HS-IT101 Injection in the Treatment of Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor.
Phase:
PHASE1
Details
Lead Sponsor:
Qingdao Sino-Cell Biomedicine Co., Ltd.
Collaborators:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences The First Hospital of Jilin University West China Hospital